Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
Psych Congress
New Orleans, LA | September 15 - 19, 2026
Auvelity® | Major Depressive Disorder
Anti-Anhedonic Effects of Auvelity® (Dextromethorphan-Bupropion) Mediate Improvements in Functioning and Quality of Life in Major Depressive Disorder
Auvelity® | Major Depressive Disorder
Anxiolytic Effects of Auvelity® (Dextromethorphan-Bupropion): Post Hoc Analyses Across Trials in Major Depressive Disorder
Auvelity® | Major Depressive Disorder
Effects of Auvelity® (Dextromethorphan-Bupropion) in Participants with Major Depressive Disorder and Anxious Distress
Auvelity® | Agitation Associated With Dementia Due to Alzheimer's Disease
Agitation in Alzheimer’s Disease: Association with Increased Clinical Burden, Healthcare Utilization, and Mortality Among Patients in Long-Term Care
Auvelity® | Major Depressive Disorder
Real-World Clinical Outcomes of Patients Switching to Treatment With Auvelity® (Dextromethorphan-Bupropion)
Auvelity® | Agitation Associated With Dementia Due to Alzheimer's Disease
Results of a Survey of Care Partners of People Living with Alzheimer’s Disease Agitation
Auvelity® | Agitation Associated With Dementia Due to Alzheimer's Disease
Real-World Treatment Patterns and Clinical Management of Alzheimer’s Disease Agitation
AXS-12 | Narcolepsy
Cognitive and Functional Outcomes From the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Study of AXS-12 in Narcolepsy with Cataplexy
AXS-12 | Narcolepsy
Symptom Burden and Quality of Life in Patients With Narcolepsy Who Experience Residual Cataplexy: Subgroup Analysis From the CRESCENDO Survey
Sunosi® | Excessive Daytime Sleepiness
Solriamfetol for Excessive Daytime Sleepiness in Narcolepsy and OSA: Post-Hoc Multi-Dimensional Composite Endpoint Analysis of Phase 3 Trials
